IGF::OT::IGF SBIR PHASE I TOPIC 331: OPTICAL BIOSENSOR FOR REAL-TIME ASSESSMENT OF TUMOR CELLULARITY DURING CORE NEEDLE BIOPSY

物理科学公司(PSI)将与MD安德森癌症中心合作，开发和测试一种在核心针刺活检过程中实时评估肿瘤细胞密度的新技术。这项技术将解决医生在进行活组织检查时遇到的主要问题之一：由于肿瘤的异质性(活肿瘤、坏死、纤维化和炎症的混合物)，无法收集足够或足够的材料进行组织学分析。因此，活检成功率从70%到95%不等，这取决于医生的技能、肿瘤大小和活检位置。不幸的是，即使在超声或CT的引导下，肿瘤的细胞性仍然是一个问题，因为这些成像方式缺乏分辨率，不能确切地区分肿块的哪些区域包含有活性的肿瘤组织。为了解决这个问题，PSI将通过提供由光学生物传感器捕获的实时肿瘤细胞数据来帮助活检过程，该光学生物传感器将调查被调查的肿块的形态和生化特征，以便能够可靠地检测到高肿瘤含量区域。这项技术将首先在组织样本上进行体外测试，然后在癌症动物模型上测试其是否适合体内使用。

Physical Sciences, Inc. (PSI), in collaboration with MD Anderson Cancer Center, will develop and test a novel technology for real-time assessment of tumor cellularity during core needle biopsy procedures. This technology will address one of the main issues that physicians encounter when performing biopsies: inability of collecting sufficient or adequate material for histological analysis due to tumor heterogeneity (mixture of viable tumor, necrosis, fibrosis and inflammation). As a result, biopsy success ranges from 70 to 95%, depending on the physician skills, tumor size, and biopsy location. Unfortunately, even when guided by ultrasound or CT, tumor cellularity remains an issue due to lack of resolution of these imagining modalities which cannot distinguish with certainty what areas of a mass contain viable tumor tissue. To address this problem PSI will aid the biopsy process by providing real-time tumor cellularity data captured by an optical biosensor which will investigate the morphology and the biochemical signature of the investigated mass, such that high tumor content regions can be reliably detected. The technology will be first tested ex vivo on tissue specimens and then its suitability for in vivo use will be tested on an animal model of cancer.